Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics


Terns Pharmaceuticals, Inc. (TERN): $2.40

0.12 (+5.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TERN Stock Price Chart Interactive Chart >

Price chart for TERN

TERN Price/Volume Stats

Current price $2.40 52-week high $13.77
Prev. close $2.28 52-week low $1.45
Day low $2.19 Volume 96,200
Day high $2.48 Avg. volume 117,974
50-day MA $1.84 Dividend yield N/A
200-day MA $5.33 Market Cap 60.67M

Terns Pharmaceuticals, Inc. (TERN) Company Bio


Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.


TERN Latest News Stream


Event/Time News Detail
Loading, please wait...

TERN Latest Social Stream


Loading social stream, please wait...

View Full TERN Social Stream

Latest TERN News From Around the Web

Below are the latest news stories about Terns Pharmaceuticals Inc that investors may wish to consider to help them evaluate TERN as an investment opportunity.

Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Terns Pharmaceuticals, Inc.'s ( NASDAQ:TERN ) business as it appears the...

Yahoo | February 4, 2022

Matthews International Capital Management Llc Buys Atlassian Corporation PLC, Pinduoduo Inc, ...

San Francisco, CA, based Investment company Matthews International Capital Management Llc (Current Portfolio) buys Atlassian Corporation PLC, Pinduoduo Inc, Full Truck Alliance Co, TDCX Inc, Lam Research Corp, sells Sea, Bilibili Inc, XPeng Inc, MINISO Group Holding, Taiwan Semiconductor Manufacturing Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Matthews International Capital Management Llc.

Yahoo | February 2, 2022

Terns Pharmaceuticals (TERN) Investor Presentation - slideshow

No summary available.

Seeking Alpha | January 15, 2022

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced the appointment of Jeffrey R. Jasper, Ph.D., as senior vice president, head of research. Dr. Jasper joins Terns with more than 28 years of experience in

Yahoo | January 6, 2022

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company’s management team will present at the following investor conferences in January: 40th Annual J.P. Morgan Health Care Conference Date: J

Yahoo | January 3, 2022

Read More 'TERN' Stories Here

TERN Price Returns

1-mo N/A
3-mo -19.19%
6-mo -66.05%
1-year -80.69%
3-year N/A
5-year N/A
YTD -66.05%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8298 seconds.